Thursday 16 October, 2025
Objectives: At the forefront of the causes of death globally, multi-drug resistant (MDR) tuberculosis (TB) manifests severely in children, posing…
Read morePoster: Methodology - Other topics
Etravirine’s Pharmacokinetics Explored: PBPK Modeling and DDI Analysis with Efavirenz for Cancer Treatment
Thursday 16 October, 2025
Objectives: Drug repurposing is an emerging strategy in the quest for new cancer therapies, offering distinct advantages such as leveraging…
Read moreSunburst Plots for Analyzing the Impact of Drugs on CRS
Thursday 16 October, 2025
Objectives: Cytokine release syndrome (CRS) is caused by substantial, rapid release of cytokines into the circulation from immune cells, often…
Read moreDevelopment of a gestational Physiologically Based Kinetic model to predict rat dam and fetus exposure in PK-Sim/MoBi
Thursday 16 October, 2025
Introduction/Objectives: The Open Systems Pharmacology (OSP) Suite, with its two mechanistic modeling and simulation software solutions PK-Sim® and MoBi®, as…
Read moreChoice of Exposure Metric in Exposure-Response Modeling
Thursday 16 October, 2025
Introduction: Exposure-response (E-R) modeling plays an important role in model-informed drug development, especially in dose selection. A key step in…
Read moreBridging the gap between secondary pharmacology and hemodynamics findings via Quantitative Systems modelling
Thursday 16 October, 2025
Objectives: Pharmaceutical companies routinely screen compounds in vitro and in vivo to understand hemodynamics related safety risks. Our current model…
Read moreInfluential factors on the type I error rate in pharmacometrics models using individual model averaging or standard approach
Thursday 16 October, 2025
Objectives: When assessing treatment effects in clinical studies by pharmacometrics modelling, type 1 error (T1) may be inflated in presence…
Read moreQualification of the Open Systems Pharmacology PBPK modeling Platform for simulation of transporter Drug-Drug-Interactions
Thursday 16 October, 2025
Introduction: The success of applications of Physiologically based pharmacokinetic (PBPK) modeling in drug development has led regulatory agencies to demand…
Read morenonmem2mrgsolve: An R package for Automated NONMEM to mrgsolve Translation
Thursday 16 October, 2025
Introduction: Pharmacometricians often utilize multiple software, with NONMEM® (ICON plc, Dublin, Ireland) widely regarded as the current gold standard for…
Read morePredicting Progression Free Survival from Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL)
Thursday 16 October, 2025
Introduction/Objectives: Measurable Residual Disease (MRD) is detectable and often quantifiable remnant cancer cells following treatment. The association between MRD and…
Read more